Information Provided By:
Fly News Breaks for June 19, 2019
ARQL
Jun 19, 2019 | 08:55 EDT
RBC Capital analyst Gregory Ranza raised his price target on ArQule to $12 and kept his Outperform rating, citing the company's "impressive data" and "high enthusiasm" for its BTKi program ARQ 531 in B-cell malignancies demonstrated at the European Hematology Association Congress this week. The analyst adds that his new price target reflects the improving prospects for ARQ 531 success, along with his "increasing confidence" that an effective path awaits ArQule toward a "meaningful" Chronic Lymphocytic Leukemia market opportunity.
News For ARQL From the Last 2 Days
There are no results for your query ARQL